Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

WSC 2026 | Which patients with medium vessel occlusion should be considered for thrombectomy?

Fabiano Cavalcante, MD, PhD(c), Amsterdam UMC, Amsterdam, Netherlands, comments on the current uncertainty surrounding the use of thrombectomy in patients with medium vessel occlusion, highlighting the need for individualized clinical decisions and more precise evidence. Dr Cavalcante notes that recent trials have increased equipoise, creating an opportunity to randomize patients and gather more data to determine which patients may benefit from thrombectomy. This interview took place at the 18th World Stroke Congress (WSC) in Seoul, Korea.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

That’s a very good question, but I think it’s a question for which we would love to have a definitive answer. I don’t think we have yet. Of course, this is my own personal view, but we have three trials that didn’t show a benefit of thrombectomy, and we have one trial from China, but from a different population, that did show a benefit. Again, clinical decisions need to be made individualized for patients...

That’s a very good question, but I think it’s a question for which we would love to have a definitive answer. I don’t think we have yet. Of course, this is my own personal view, but we have three trials that didn’t show a benefit of thrombectomy, and we have one trial from China, but from a different population, that did show a benefit. Again, clinical decisions need to be made individualized for patients. But I think what we observed after the publication of these trials is that maybe the equipoise has become larger. Maybe before these trials, people were more convinced of the benefit of thrombectomy in this group. And maybe now there’s more space to actually randomize patients who actually might benefit from thrombectomy so that we can get a definitive answer. So though it’s not a clinically actionable recommendation, I think what we do need is still to get more precision either by combining the data of these established trials and or by conducting additional trials on this topic because I think we are still not there yet in terms of having clear evidence of which patients should be treated or not.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJNeurology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.